It’s easy to put a bottle of prescription pills in the medicine cabinet and forget about what’s on the label — until something like a recall jolts you into paying attention.
Yet medication and medical device recalls happen fairly often. On average, there are 330 drug recalls every year, according to a 2024 study published in the Journal of Pharmaceutical and Biomedical Analysis.
Drug recalls typically happen when there is contamination, such as with foreign objects like glass particles, mislabeling, adverse reactions, or defective products, including ingredients that are too potent or not potent enough. The notion that a prescription medicine could be dangerous or ineffective isn’t a small worry.
The latest recall affects a generic versions of the statin medication Atorvastatin Calcium, a medication taken by around 47 million Americans to lower “bad” cholesterol, according to Yale Medicine.
The drug is being recalled nationwide after quality failures — here’s what you need to know.
Urgent recall affects medication used by millions of Americans
The U.S. Food & Drug Administration (FDA) updated a Class II recall notice for several versions of generic Atorvastatin Calcium tablets with expiration dates through February 2027 after discovering the pills failed to meet dissolution specifications — meaning they may not dissolve as expected and thus may not be properly absorbed.
The recall was initiated on September 19, 2025, and updated on October 14, 2025.
The recall affects 141,984 bottles nationwide of the generic statin medications.
The recall covers multiple lots with expiration dates ranging from July 2026 to February 2027, the FDA said.
Affected Atorvastatin Calcium lot numbers include:
- 25141249
- 24144938
- 24144868
- 24144458
- 24143994
- 24142987
- 24143316
A complete list of lot numbers is listed here.
Importantly: the brand-name version of Atorvastatin (often sold under the name Lipitor) is not listed in this recall.
Why this cholesterol-lowering drug recall matters
Most pharmaceutical recalls are initiated by the drug manufacturers, and that appears to be the case with this one, which is made by New Jersey-based Biocon Pharma, Inc.
“Recalls are typically initiated voluntarily by companies before they notify FDA,” explained Dr. Ileana Elder, Branch Chief in the Incidents, Recalls, and Shortages Branch within the Office of Compliance in FDA’s Center for Drug Evaluation and Research in a 2024 FDA Q&A.
Source: By Dana Sullivan Kilroy TheStreet Writer/Editor thestreet.com
